MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

Core Insights - MediWound Ltd. is presenting 10 scientific abstracts at the Wound Healing Society (WHS) and the Symposium on Advanced Wound Care (SAWC) Spring 2025, focusing on EscharEx's mechanism of action and its advantages over SANTYL in treating chronic wounds [1][2][4] Company Overview - MediWound Ltd. is a global biotechnology company specializing in enzymatic therapies for non-surgical tissue repair, with its FDA-approved product NexoBrid for thermal burns [6][7] Product Information - EscharEx is a bromelain-based enzymatic therapy designed for the debridement of chronic wounds, showing a favorable safety profile and effective wound bed preparation in multiple Phase II trials [5][6] - The therapy has demonstrated the ability to remove non-viable tissue, promote granulation, and reduce bioburden and biofilm, targeting a substantial global market opportunity [5][7] Clinical Development - The ongoing VALUE Phase III study is enrolling patients with venous leg ulcers (VLUs), building on positive results from three completed Phase II studies that confirmed EscharEx's efficacy and safety [4][5] - A Phase II/III study in diabetic foot ulcers (DFUs) is in preparation, with new data supporting the planned clinical trial strategy [2][5] Conference Highlights - Key presentations at WHS and SAWC will include new in vitro data on EscharEx's multitargeted proteolytic activity, case studies in advanced DFUs and VLUs, and updates on the VALUE Phase III study design and enrollment progress [6][8]